Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Company Overview - Solid Biosciences is a precision genetic medicine company with approximately 120 employees, primarily focusing on gene therapies [2] - The company has three main drug candidates: one for Duchenne Muscular Dystrophy, another for Friedreich’s Ataxia, and a third for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [2] Product Pipeline - The next program in development targets dilated cardiomyopathies, specifically TNNT2 [3] - Solid Biosciences is building a comprehensive capsid library and platform to enhance gene therapy delivery, focusing on capsids, promoters, dual plasmids, and manufacturing purity [3]